|
|
Article: Novel medicine to prevent fungal infections.(Updates)
- Article from:
- FDA Consumer
- Article date:
- November 1, 2006
CopyrightCOPYRIGHT 2006 U.S. Government Printing Office. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Noxafil (posaconazole) has been approved to prevent fungal infections caused by certain molds and yeast-like fungus called Aspergillus and Candida. The FDA approved the drug in September for use in people who have weakened immune systems after bone marrow transplants and for people with decreased white blood cell counts that make it difficult for the body to fight infections after chemotherapy for cancer.
Noxafil is an antifungal drug which contains an active substance that has never before been approved for marketing in any form in the United States.
The safety and effectiveness of Noxafil were evaluated in clinical trials consisting of 1,844 people ...